[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344149-105":59,"doc-detail-344149-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","access-to-and-utilization-of-endocrine-therapy-among-breast-cancer-survivors-in-botswana","Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana","","The study examines how breast cancer survivors in Botswana access and use endocrine therapy (ET), a key treatment for hormone receptor–positive disease. It analyzes semi-structured interviews from a survivorship cohort, focusing on women for whom ET was indicated and those reporting ET use. Findings identify multilevel barriers including limited provider counseling, difficulties refilling prescriptions in public pharmacies, and high costs and transportation burdens tied to private pharmacies. Supportive persistence, socioeconomic position, and financial assistance facilitate refills, while side effects are not a dominant discontinuation driver.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/access-to-and-utilization-of-endocrine-therapy-among-breast-cancer-survivors-in-botswana/344149/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/access-to-and-utilization-of-endocrine-therapy-among-breast-cancer-survivors-in-botswana/344149.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main objective in Botswana?","Question",{"text":112,"@type":113},"To understand breast cancer survivors’ experiences and challenges with initiating, adhering to, and accessing endocrine therapy (ET) in Botswana.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What barriers to endocrine therapy utilization were identified?",{"text":117,"@type":113},"Barriers included limited provider counseling, public pharmacy prescription refill challenges and stockouts, and high medication plus transportation costs associated with private pharmacies.",{"name":119,"@type":110,"acceptedAnswer":120},"Did side effects play a major role in stopping endocrine therapy?",{"text":121,"@type":113},"Although some survivors experienced side effects, side effects were not a common reason for discontinuation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344149,1790508825,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Original Reports | Breast Cancer  \nAccess to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana  \nJames R. Wester, MD1 ; Rachel B. Wagner, MA2 ; Bosa Motladiile, MPH3; Isaac Nkele, RN3; Nkhabe Chinyepi, MD4  ;  \nMoeketsi J. Makhema, MBBS3; Tara M. Friebel-Klingner, PhD5 ; Peter Vuylsteke, MD6 ; Shahin Lockman, MD3,7,8 ;  \nScott Dryden-Peterson, MD3,7,8 ; and Racquel E. Kohler, PhD, MSPH2,3  DOI [https://doi.org/10.1200/GO.24.00180](https://doi.org/10.1200/GO.24.00180)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Breast cancer (BC) is the most common female cancer worldwide, and the burden is increasing across sub-Saharan Africa. For women with hormone receptor–positive (HR1) cancers, endocrine therapy (ET) taken for 5-10 years can reduce the risk of recurrence by half. We explored experiences with ET and barriers to utilization among survivors in Botswana. |\n| METHODS | We recruited women with nonmetastatic disease from a survivorship cohort who had undergone mastectomy within 1-5 years for semi-structured interviews to explore experiences with treatment. This thematic content analysis focused on ET, so the sample included women with HR1cancer who should have received ET and HR 2 women who reported taking ET. |\n| RESULTS | We analyzed interviews with 19 women (mean age 54 years, 42% stage I/II, 58% stage III). Three key themes were identiﬁed: (1) limited provider counseling,(2) challenges reﬁlling prescriptions at public pharmacies, and (3) high medication and transportation costs associated with private pharmacies. Subthemes included immunohistochemistry result communication, lack of knowledge, frequent public pharmacy stockouts, inconvenient prescription reﬁll policies, and medication switching and discontinuation, especially among participants with low socioeconomic positions (SEPs) . Women’s persistence, SEP, and ﬁ nancial support facilitated reﬁlls. Although some experienced side effects, they were not a common reason for discontinuation. |\n| CONCLUSION | BC survivors in Botswana face multilevel barriers to accessing and adhering to ET. Provider and health system improvements are needed to effectively communicate ET importance and increase access to consistently available and affordable medication. |\n\nAccepted October 25, 2024 Published December 12, 2024  \nJCO Global Oncol 10:e2400180 © 2024 by American Society of Clinical Oncology  \nLicensed under the Creative  \nCommons Attribution 4.0 License  \nINTRODUCTION  \nGlobally, breast cancer (BC) was the most commonly diagnosed malignancy and the leading cause of cancer death among females in 2022 .1 The incidence is projected to continue increasing in multiple countries across subSaharan Africa (SSA) .2-4 SSA has the highest incidence-tomortality ratio, largely due to 50%-90% of cases being diagnosed with advanced disease and lack of screening.5-7 In many of these settings, BC disproportionately affects women under age 50 years,8,9 and nearly two thirds of patientsin SSAare hormone receptor–positive (HR1) .10,11  \nFor women with HR1 BC, endocrine therapy (ET) for 5- 10 years can reduce the risk of recurrence by half.12-15 Tamoxifen, which has been on the WHO Essential Medicines List for a few decades,16 is recommended as part of  \ncomprehensive BC management17,18 and an affordable aspect of survivorship care.19-21 However, studies from multiple low- and middle-income countries (LMICs) have found that adherence varies, particularly among younger women.22-25 Reasons for nonadherence in LMICs include side effects,26-28 costs,29-31 and socioeconomic position (SEP) .32-34 Comorbidities,35 like living with HIV,25 also inﬂuence adherence. However, few studies have examined ET experiences and adherence in SSA.36,37  \nIn Botswana, a middle-income country in SSA, the majority (68%) of patients with BC are diagnosed with advanced disease and nearly 70% have HR1 cancers.38,39 The median age at diagnosis is 54 years.11 However, women living with HIV (WLWH) tend t","cbCaivKtsIo3yjXM","https://ap.wps.com/l/cbCaivKtsIo3yjXM","pdf",473026,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance\n# Introduction\n## Background\n## Rationale for the Study\n# Methods\n## Setting","[{\"question\":\"What was the study’s main objective in Botswana?\",\"answer\":\"To understand breast cancer survivors’ experiences and challenges with initiating, adhering to, and accessing endocrine therapy (ET) in Botswana.\"},{\"question\":\"What barriers to endocrine therapy utilization were identified?\",\"answer\":\"Barriers included limited provider counseling, public pharmacy prescription refill challenges and stockouts, and high medication plus transportation costs associated with private pharmacies.\"},{\"question\":\"Did side effects play a major role in stopping endocrine therapy?\",\"answer\":\"Although some survivors experienced side effects, side effects were not a common reason for discontinuation.\"}]","Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana | PDF",1790053120,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8bf7ea50b46f27a7f41165228bdff1e.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97b913e2611b34bab4f1dd1eb6635d5b.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de07ec62380f63466d0a8bc506104c35.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1e05f07afce4ef49e5c2787b4165963.webp",980,1311]